Efficacy and Safety Evaluation of Rifaximin Combined Fecal Microbiota Transplantation in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea
Phase of Trial: Phase II/III
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Rifaximin (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- 10 Apr 2017 Planned number of patients changed from 200 to 10.
- 10 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2017.
- 05 Feb 2016 New trial record